Genedata Launches AI Platform for Drug Manufacturing and Development

Genedata, a company under Danaher Corporation, announced in a press release the launch of Genedata Vico, an AI based platform designed to accelerate Chemistry, Manufacturing, and Controls (CMC) processes in drug development and production. The solution was co-developed with several top ten pharmaceutical companies and recognized by Bio-IT World with the 2026 Innovative Practices Award for Real-World AI.

Genedata Vico integrates experimental data and metadata from multiple sources across biologics and small molecule development to create analysis ready datasets that maintain context and lineage. It supports CMC data scientists in applying proprietary or commercial AI models with full tracking and lifecycle management, allowing teams to visualize and analyze data supported by domain specific AI agents.

The platform enables AI assisted process analytical technology for monitoring drug quality during production and supports data based design of experiments and quality by design methods. It is built on Anthropic's Claude model family and includes a GxP compliant Model Context Protocol server for integration into enterprise frameworks.

According to benchmarking by its pharmaceutical partners, use of Genedata Vico can recover up to 80 percent of losses typically incurred from failed batches and avoid up to 15 months of clinical trial supply delays each year. The company plans to present the platform and its performance results at the Bio-IT World Conference and Expo.